Patents Represented by Attorney, Agent or Law Firm Vandana Date
-
Patent number: 6699497Abstract: Composition of matter for application to a body surface or membrane to administer fenoldopam by permeation through the body surface or membrane, the composition comprising fenoldopam to be administered, at a therapeutically effective rate, in combination with a permeation enhancer or mixture. Also disclosed are drug delivery devices and methods for the transdermal administration of fenoldopam for the treatment of hypertension, congestive heart failure, and chronic and acute renal failure.Type: GrantFiled: July 23, 1999Date of Patent: March 2, 2004Assignee: Alza CorporationInventors: William W. van Osdol, Nieves M. Crisologo, Su Il Yum
-
Patent number: 6673767Abstract: Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, compositions having burst indices of 8 or less for systemic applications and systems releasing 10% or less of the total dose of beneficial agent in the first 24 hours after implantation for local applications. The compositions include a biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.Type: GrantFiled: March 21, 2000Date of Patent: January 6, 2004Assignee: Alza CorporationInventors: Kevin J. Brodbeck, Ann T. Gaynor-Duarte, Theodore Tao-Ian Shen
-
Patent number: 6660295Abstract: This invention relates to the field of transdermal drug delivery devices and more particularly to improved storage stability thereof. The invention comprises providing a transdermal drug delivery device with a non-occlusive backing or release liner in combination with a degradation protectant such as a desiccant or oxygen scavenger within the sealed pouch containing the device. The combination of the present invention provides increased shelf-life of these devices.Type: GrantFiled: September 29, 1998Date of Patent: December 9, 2003Assignee: Alza CorporationInventors: Tyler Watanabe, Robert M. Gale
-
Patent number: 6572879Abstract: Composition of matter for application to a body surface or membrane to administer pergolide by permeation through the body surface or membrane, the composition comprising pergolide to be administered, at a therapeutically effective rate, alone or in combination with a permeation enhancer or mixture. Also disclosed are drug delivery devices containing the pergolide or pergolide and enhancer composition and methods for the transdermal administration of the pergolide and pergolide/enhancer composition.Type: GrantFiled: June 7, 1995Date of Patent: June 3, 2003Assignee: Alza CorporationInventors: Su Il Yum, Melinda K. Nelson, Patricia S. Campbell
-
Patent number: 6569448Abstract: An improved method for the manufacture of transdermal drug delivery devices comprising liquid dispersions of a liquid in an aqueous or nonaqueous matrix is disclosed. More particularly, the invention relates to preventing the formation of a crystalline structure in such liquid dispersions by annealing films and laminates in-line immediately following film formation and/or lamination during the manufacture of these devices.Type: GrantFiled: October 17, 1997Date of Patent: May 27, 2003Assignee: Alza CorporationInventors: John W. Dohner, Scott A. Bura, Richard E. Ford
-
Patent number: 6512010Abstract: Composition of matter for application to a body surface or membrane to administer fluoxetine by permeation through the body surface or membrane, the composition comprising fluoxetine to be administered, at a therapeutically effective rate, alone or in combination with a permeation enhancer or mixture. A preferred embodiment is directed to the transdermal administration of fluoxetine at reduced skin irritation levels wherein fluoxetine, preferably provided as fluoxetine acetate, is coadministered with a corticosteroid such as hydrocortisone. Also disclosed are drug delivery devices containing the fluoxetine or fluoxetine and enhancer composition and methods for the transdermal administration of the fluoxetine and fluoxetine/enhancer composition.Type: GrantFiled: July 14, 1997Date of Patent: January 28, 2003Assignee: Alza CorporationInventors: Robert M. Gale, Melinda K. Nelson, Michel J. N. Cormier, Suneel K. Gupta, Patricia S. Campbell
-
Patent number: 6468961Abstract: Methods and compositions for systemically or locally administering by implantation a beneficial agent to a subject are described, and include, for example, compositions having burst indices of 8 or less for systemic applications and systems releasing 10% or less of the total dose of beneficial agent in the first 24 hours after implantation for local applications. The compositions include a biocompatible polymer, a biocompatible solvent having low water miscibility that forms a viscous gel with the polymer and limits water uptake by the implant, and a beneficial agent.Type: GrantFiled: July 13, 2000Date of Patent: October 22, 2002Assignee: Alza CorporationInventors: Kevin J. Brodbeck, Ann T. Gaynor-Duarte, Theodore Tao-Ian Shen
-
Patent number: 6375978Abstract: This invention provides rate controlling membranes for controlled drug delivery devices that are stable over time and exhibit more predictable and consistent membrane functionality. According to another aspect, the membranes have enhanced permeability. According to the invention, the rate controlling membrane of a controlled drug delivery device is subjected to a pre-treatment annealing process wherein it is subjected to an elevated temperature for a predetermined time period and subsequently cooled to ambient conditions before incorporation into a controlled drug delivery device.Type: GrantFiled: December 17, 1998Date of Patent: April 23, 2002Assignee: ALZA CorporationInventors: Lothar W. Kleiner, Robert M. Gale, Randall G. Berggren, Gilbert T. Tong, Guohua Chen, Keith E. Dionne, Paul R. Houston
-
Patent number: 6355641Abstract: This invention relates to compounds which are generally alpha1B-receptor antagonists, and which are represented by Formula (I): wherein X, Y, and R1 are as defined in the specification, or individual isomers or racemic or non-racemic mixtures of isomers, or pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing such compounds, and methods for their use as therapeutic agents.Type: GrantFiled: March 8, 2000Date of Patent: March 12, 2002Assignee: Syntex (U.S.A.) LLCInventors: David Llewellyn Coffen, Michael Patrick Dillon, Anthony P. D. W. Ford, Zhe Li, Timothy James Williams
-
Patent number: 6348210Abstract: Adhesive transdermal drug delivery devices may be removed and subsequently reapplied to an area of skin if the adhesive has an initial adhesive/skin bond strength sufficient to maintain said transdermal drug delivery device on the skin to which it is applied for the entire predetermined administration period; and an adhesive/skin bond strength upon replacement on the skin after removal therefrom which is adequate to retain the device on the skin for the balance of the administration period.Type: GrantFiled: November 10, 1999Date of Patent: February 19, 2002Assignee: Alza CorporationInventor: Robert Martin Gale
-
Patent number: 6267984Abstract: Compositions, devices, and methods for transdermal administration of a drug are disclosed using a novel permeation enhancer mixture comprising a monoglyceride and ethyl palmitate. The monoglyceride/ethyl palmitate permeation enhancer is a potent permeation enhancer and provides stable systems which are more readily characterized. Additionally, ethyl palmitate cosolvent systems are more readily processed at manufacturing conditions thus providing further advantages over other cosolvents.Type: GrantFiled: December 17, 1998Date of Patent: July 31, 2001Assignee: ALZA CorporationInventors: Russell D. Beste, Richard D. Hamlin
-
Patent number: 6203817Abstract: Transdermal compositions, devices, and methods for the administration of a drug at reduced skin irritation levels are disclosed. More particularly, this invention relates to novel methods, compositions, and devices for the reduction or elimination of irritation or sensitization caused by an irritating or sensitizing drug when it is delivered transdermally. According to a preferred embodiment, transdermal administration of a drug salt of a non-zwitterionic drug is disclosed wherein the drug salt comprises a combination of surface activity and a low octanol-water partition coefficient. Such drug salts have been found to reduce irritation or sensitization to the drug being delivered while achieving therapeutically effective transdermal fluxes.Type: GrantFiled: June 5, 1998Date of Patent: March 20, 2001Assignee: ALZA CorporationInventors: Michel J. N. Cormier, Peter E. Daddona, Juanita A. Johnson
-
Patent number: 6174545Abstract: An improved process for manufacturing transdermal drug delivery devices and devices made therefrom. The invention provides a heat equilibration process for the manufacture of drug delivery devices which eliminates the need to preload the body contacting layer with a drug. The method has particular application in the manufacture of transdermal drug delivery devices including a drug reservoir comprising drug in excess of saturation.Type: GrantFiled: February 3, 1999Date of Patent: January 16, 2001Assignee: Alza CorporationInventors: David J. Enscore, Patricia S. Campbell, Diane Nedberge, Richard D. Frame
-
Patent number: 5440015Abstract: Peptides are described and methods of using the peptides to treat or prevent disease which peptides are described by the formula:SEQ. ID NO:1wherein X is an aromatic amino acid, and n is 1, 2, or 3; X' is either a non-polar or polar uncharged amino acid, and n' is 1, 2, or 3; X" is a basic amino acid, and n" is 1 or 2.Type: GrantFiled: March 29, 1993Date of Patent: August 8, 1995Assignee: Glycomed IncorporatedInventors: Bruce A. Macher, John B. Briggs